Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medilink West Midlands relocates with UK innovation premiership aspirations:

This article was originally published in Clinica

Executive Summary

UK regional medtech development office Medilink West Midlands is relocating from its Wolverhampton offices at the Science Park, to the centre of Birmingham. The move seeks to support the development of the West Midlands "as the premier location for the medical and healthcare industry". Plans to expand and develop its services will be bolstered by the fact that it will be co-locating with MidTech, the region's NHS Innovation hub, said Medilink West Midlands. Its new contact details are: 5 Greenfield Crescent, Edgbaston, Birmingham B15 3BE. Tel (from December 20): + 44 (0)121 452 5630; email: [email protected]

You may also be interested in...



MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’

The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT058167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel